Alzinova Q1 2023: Promising clinical progress - Redeye

Redeye leaves a comment on the Q1 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, we are encouraged by the clinical and financial progress of the company during the period. We reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/909121/alzinova-q1-2023-promising-clinical-progress?utm_source=finwire&utm_medium=RSS